Asthma and COPD drugs: efficacy, safety and pharmacoeconomics

Thematic Poster Session
Chairs: P. Chanez (Marseille, France), M. Cazzola (Rome, Italy), M. Edwards (London, United Kingdom), L. Uller (Lund, Sweden)

Download all media

Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149 S. Shimada, S. Vaidya, S. Khindri, N. Tashiro, B. Patterson, R. Woessner, K. Kobayashi, K. Furihata (Tokyo, Japan; Cambridge, United States Of America; Horsham, United Kingdom; Basel, Switzerland)
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies R. Mehta, A. Preece, A. Newlands, J. Blowers, A. Cahn (Research Triangle Park, United States Of America; Stockley Park, Stevenage, United Kingdom)
Pharmacodynamics (PD) of low and high strength budesonide plus formoterol (BF) Spiromax® and BF Turbuhaler® in healthy volunteers (HV) L. Weisfeld, G. Gopalan, Y. Shu, B. Baconnet, T. Shah (Miami, Frazer, United States Of America; Maisons Alfort, France)
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI W. Azouz, P. Chetcuti, H. Hosker, D. Saralaya, H. Chrystyn (Huddersfield, Leeds, Steeton, Keighley, Bradford, United Kingdom)
Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease W. Sirichana, C. H. Tseng, I. Barjaktarevic, E. C. Kleerup, C. B. Cooper (Los Angeles, United States Of America; Bangkok, Thailand)
Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes C. Vogelmeier, R. Dahl, A. D'Urzo, H. Chen, Y. Green, D. Banerji (Marburg, Germany; Aarhus, Denmark; Ontario, Canada; East Hanover, United States Of America; Horsham, United Kingdom)
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study J. A. Wedzicha, M. Decramer, J. Vestbo, N. Gallagher, H. J. Kim, D. McBryan, D. Banerji (London, Manchester, Horsham, United Kingdom; Leuven, Belgium; East Hanover, United States Of America; Basel, Switzerland)
Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients X. Huang, X. Liu, Y. Luo, Y. Zhou, Y. Guo, C. Xie (Guangzhou, Meizhou, China)
Contraindications and precautions with inhalation therapy in COPD. Awareness or unawareness, a questionaire C. N. Meyer (Roskilde, Denmark)
The clinical impact of long-acting bronchodilators in newly diagnosed COPD patients S. W. Lee, J. Kim, Y. M. Oh, S. D. Lee (Seoul, Republic Of Korea)
Inhaler technique: An unmet need in patients with difficult asthma? T. Capstick, I. Clifton, J. Morgan, J. Silcock, A. Blenkinsopp (Leeds, Bradford, United Kingdom)
Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma H. Svedsater, L. Jacques, C. Goldfrad, E. R. Bleecker, P. M. O'Byrne, A. Woodcock (London, Manchester, United Kingdom; Winston-Salem, United States Of America; Hamilton, Canada)
Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI G. Ciurlia, A. Piccinno, R. Baronio, D. Acerbi (Parma, Italy)
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma J. Gogtay, S. Salvi, A. Balki, R. Dhar, M. Ahmed, M. Jain, S. Dalal, S. Tikkiwal, R. Bhagat, P. Phopale, S. Jadhav, A. Vaidya (Mumbai, Pune, Nagpur, Kolkata, Aurangabad, Jaipur, Vadodara, Ahmedabad, India)
Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone A. Papi, D. Price, J. Sastre, K. Kaiser, M. Lomax, T. McIver, S. Dissanayake (Ferrara, Italy; Aberdeen, Cambridge, United Kingdom; Madrid, Spain; Muttenz, Switzerland)
Montelukast improves air trapping, not airway remodeling, in moderate-to-severe patients with asthma: A pilot tudy J. Gao, F. Cai, B. Wang (Beijing, China)
Changes in body composition are associated with corticosteroid use in adult asthma B. Berthon, L. MacDonald-Wicks, P. Gibson, L. Wood (Callaghan, Australia)
The impact of asthma severity on the total cost of asthma patients in the Valencia Region L. Lizán, C. álvarez Sanz, M. E. Ojanguren, M. Capel, S. Paz, E. Compes García, J. J. Liñana Santafé, G. Mencia Sánchez, L. A. Navarro Seisdedos, J. Pascual Bernabeu, F. Sánchez-Toril (Castellón, Madrid, Zaragoza, Valencia, Alicante, Spain)
Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis Z. Diamant, L. Franciosi, N. Morelli, R. Zuiker, I. Kamerling, M. de Kam, K. Burggraaf, A. Cohen, M. Walker, C. Page (Lund, Sweden; Groningen, Leiden, Netherlands; London, United Kingdom; Vancouver, Canada)